Lazanda
Product Images NDC 51772-311

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Lazanda (NDC 51772-311). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Archimedes Pharma Us Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Flow Chart (Lazanda 01)

Flowchart illustrating the titration process for Lazanda nasal spray. It starts with a 100 mcg dose (one spray in one nostril), followed by waiting at least 2 hours before the next dose. After 30 minutes, pain relief adequacy is assessed to decide continuation or dose increase, leading to identification of the successful dose.*

FDA Label Image

Chemical Structure (Lazanda 02)

Chemical structure of the active ingredient in LAZANDA by Archimedes Pharma US Inc., showing molecular components with phenyl groups, piperidine rings, and functional groups typical for this formulation.*

FDA Label Image

Fig 1 (Lazanda 03)

A line graph depicting the mean plasma fentanyl concentration (pg/mL) over time (hours) for Lazanda nasal spray at doses of 100, 200, 400, and 800 mcg, compared with OTFC at 200 mcg. The y-axis shows fentanyl levels, and the x-axis shows time up to 4 hours, with error bars indicating standard deviation.*

FDA Label Image

Fig 2 (Lazanda 04)

A line graph comparing PID (standard error) over time (minutes) between Lazanda and placebo groups. Lazanda shows higher PID values at all time points up to 60 minutes, with both groups showing an increasing trend over time.*

FDA Label Image

Figure (Lazanda 05)

An instructional diagram showing components of the LAZANDA fentanyl nasal spray packaging, including a child-resistant container, disposal pouch, the spray bottle with protective cap, nozzle tip, grips, and counting window. The spray bottle label displays 100 mcg per spray dosage information and branding.*

FDA Label Image

Figure (Lazanda 06)

Disposable pouch packaging label for Lazanda by Archimedes Pharma US Inc. The label includes instructions to open the pouch by removing a seal and flipping the top cover, and advises to use the contents only with Lazanda nasal spray. A barcode is visible at the bottom of the label.*

FDA Label Image

Figure (Lazanda 07)

An instructional illustration focusing on the top part of a container cap. The cap shown is white with a raised tab, highlighted by an arrow and label indicating "cap with raised tab." The image is labeled as Figure C.*

FDA Label Image

Figure (Lazanda 08)

Illustration showing two steps in the use of LAZANDA, a nasal spray. Figure D depicts a hand holding the spray bottle with the cap being removed. Figure E shows attaching a labeled medication vial to the spray bottle, demonstrating preparation for administration.*

FDA Label Image

Figure (Lazanda 09)

An illustration showing five figures (F to J) depicting different colored indicator tips on the top part of the LAZANDA spray device. The colors shown are various patterns of red and white for Figures F to I, and green and white for Figure J. This likely relates to usage or dosage indication of the LAZANDA nasal spray device by Archimedes Pharma US Inc.*

FDA Label Image

Figure (Lazanda 10)

LAZANDA nasal spray bottle shown held in a person's hand. The bottle is white with a label containing text and a green square logo above the product name. The image highlights the container design, including the nasal spray applicator and label details, associated with Archimedes Pharma US Inc.*

FDA Label Image

Figure (Lazanda 11)

Illustrations labeled as Figure L and Figure M showing close-up views of a nasal spray device's tip. Figure L displays the spray tip with a green indicator, while Figure M shows the tip with a black number '1' marking, likely representing usage or position instructions for the device.*

FDA Label Image

Figure (Lazanda 12)

An instructional illustration showing the use of LAZANDA nasal spray by an older man. The sequence depicts holding the spray bottle, positioning it near the nostril, and spraying into the nose to demonstrate proper administration technique.*

FDA Label Image

Figure (Lazanda 13)

An instructional image showing a hand placing a white sponge applicator into the nozzle of a nasal spray bottle, demonstrating preparation or use steps of the LAZANDA nasal spray product by Archimedes Pharma US Inc.*

FDA Label Image

Figure (Lazanda 14)

An instructional illustration showing two views of the LAZANDA nasal spray device by Archimedes Pharma US Inc. Figure R depicts a person holding and preparing the device by removing the protective cap. Figure S shows a close-up of the device nozzle with an orange indicator marked "8".*

FDA Label Image

Figure (Lazanda 15)

Two images show hands opening a LAZANDA medication packet. The first image (Figure T) depicts peeling open the top flap of the packet, while the second image (Figure U) shows further opening to access the contents. The packet label includes the proprietary name LAZANDA and a barcode, indicating it is a single-use dose packaging from Archimedes Pharma US Inc.*

FDA Label Image

Principal Display Panel (100 mcg Carton)

LAZANDA fentanyl nasal spray packaging label showing 100 mcg per spray strength. The label includes product name and dosage form, manufacturer Archimedes Pharma US Inc., and packaging content details of 4 bottles, each containing 8 sprays. Warning and important safety information for caregivers and patients are also visible, along with storage and inactive ingredients information. A barcode and pharmacy label placement area are present as well.*

FDA Label Image

Principal Display Panel (400 mcg Carton)

Label for Lazanda fentanyl nasal spray 400 mcg per spray by Archimedes Pharma US Inc. The label states it is for nasal administration only, with 4 bottles containing 8 sprays each. It includes warnings about opioid therapy tolerance, storage instructions, inactive ingredients, and distribution through the TIRF REMS Access program. Barcode and manufacturer information are also visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.